These data put forward the involvement of Transforming growth factor beta 1 (TGFB1), an inhibitor of microglial inflammatory processes in murine models of PD (Chen et al., 2017), and matrix metallopeptidase 2 (MMP2), known to degrade α-synuclein aggregates (Oh et al., 2017). This evidence concerns the gene MMP2 and Parkinson disease.